Athersys

Overselling stem cells for COVID-19: WSJ article & UMN PR

EM-of-Novel-Coronavirus-SARS-CoV-2-that-causes-COVID-19

Many are  jumping on the bandwagon of trying stem cells for COVID-19 or testing other cellular therapies for the novel coronavirus disease, but there have been problems with either the rationales for the trials themselves or more often with how they portrayed. Sometimes there has even been outright hype. I’ve called this collective trend of …

Overselling stem cells for COVID-19: WSJ article & UMN PR Read More »

BARDA drops funding of research into stem cells for COVID-19

Rick-Bright-BARDA

Katie Thomas at the New York Times reports that BARDA has dropped considering funding applications for stem cells for COVID-19. The move is part of a larger shift in funding priorities away from lung treatments and toward vaccine development. The decision has puzzled and even angered some stem cell firms and researchers. BARDA stands for …

BARDA drops funding of research into stem cells for COVID-19 Read More »

Update on stem cells for COVID-19, Surgisphere scandal

Stem-cells-for-COVID-19-Maryland

The term Regenerative Medicine covers so much biomedical science these days including everything from just about any kind of cell therapy (not just stem cells) to CRISPR gene editing, and with the the COVID-19 pandemic, it seems this umbrella use of the term now includes potential treatment of viral illnesses. It can be hard to …

Update on stem cells for COVID-19, Surgisphere scandal Read More »

Field throws stem cells for COVID-19 like spaghetti on the wall

Hype

The idea of testing stem cells for COVID-19 may be music to the ears of some folks as an opportunity, but to me from the beginning it sounded mostly like a spaghetti on the wall road to trouble. There is buzz out there that some kind of stem cells or other cells will help with …

Field throws stem cells for COVID-19 like spaghetti on the wall Read More »

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more

EM-of-Novel-Coronavirus-SARS-CoV-2-that-causes-COVID-19

  It’s been a busy week for the cellular and regenerative medicine space for COVID-19 news with some possible ups including for Mesoblast and some definite downs. Starting with the more positive media buzz with have Mesoblast. Mesoblast made COVID19 news “Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of an …

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more Read More »

Cell therapy trials for COVID-19 accelerate & some early reports

MultiStem-Athersys-cell-therapy-COVID-19

Could various kinds of cell therapy help patients with COVID-19? A variety of cell therapies, mostly focused on mesenchymal stromal/stem cells (MSCs), have gotten cleared quickly in the U.S., China, and Israel and possibly other countries to be tested in patients with the novel coronavirus. I hope at least one proves helpful. It’s mostly a …

Cell therapy trials for COVID-19 accelerate & some early reports Read More »

Athersys & Mesoblast stem cells for COVID-19?

2019-nCoV-COVID-19-Pasteur

Could two stem cell biotechs Athersys and Mesoblast help in the battle against the novel coronavirus disease COVID-19? Stem cells, ARDS, and COVID-19 I’ve already written two pieces about the idea of using stem cells to battle COVID-19 (here and here), the sometimes fatal disease that arises from infection with the novel coronavirus. Older patients …

Athersys & Mesoblast stem cells for COVID-19? Read More »

Mesoblast gets FDA RMAT; List of 10 total designations so far

Mesoblast-e1514313188176

Australian stem cell biotech Mesoblast announced that it has received regenerative medicine advanced therapy (RMAT) designation from the U.S. FDA. This is very good news for the company and an encouraging development for the field. Interestingly, last month the FDA clarified that there is expanded RMAT designation that can include gene therapies too. At the Meeting …

Mesoblast gets FDA RMAT; List of 10 total designations so far Read More »